<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> is a leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> in the United States, and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is a major risk factor for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Our previous work showed that type II diabetic rats [Goto-Kakizaki (GK)] have more <z:mp ids='MP_0001914'>bleeding</z:mp> after <z:hpo ids='HP_0001297'>stroke</z:hpo> than their normoglycemic controls (Wistar) </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to evaluate the vascular protective properties of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> therapy after experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp> and to explore the effect of <z:hpo ids='HP_0001297'>stroke</z:hpo> in GK rats compared with their normoglycemic controls </plain></SENT>
<SENT sid="3" pm="."><plain>Fifty male Wistar and 40 GK rats (270-305 g) underwent 3 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by reperfusion for 21 h </plain></SENT>
<SENT sid="4" pm="."><plain>Animals received <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (5 mg/kg), <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> (15 mg/kg), or vehicle, administered by oral gavage, one dose 5 min after reperfusion and a second dose after 12 h </plain></SENT>
<SENT sid="5" pm="."><plain>At 24 h, functional outcome was measured, and brain tissue was analyzed for <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content, and molecular biomarkers </plain></SENT>
<SENT sid="6" pm="."><plain>Plasma was collected for analysis of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> concentrations </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi>-treated groups had significantly lower <z:mp ids='MP_0001914'>bleeding</z:mp> rates (p = 0.0011) and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (p = 0.0007) compared with controls </plain></SENT>
<SENT sid="8" pm="."><plain>There was a significant reduction in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume only in the higher dose group (15 mg/kg) (p &lt; 0.05), and these benefits were more than 4 times greater in the diabetic animals </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> (15 mg/kg) improved neurological outcome in both Wistar and GK rats (p = 0.029) at a peak concentration of 27 to 77 ng/ml and was associated with an increase in Akt phosphorylation (p = 0.0007) </plain></SENT>
<SENT sid="10" pm="."><plain>We concluded that <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> is a vascular <z:chebi fb="1" ids="50267">protective agent</z:chebi> after experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, especially in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>